NervGen Pharma Grants Stock Options

Rhea-AI Summary

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced the granting of 627,200 incentive stock options. The options were distributed to company employees, with 505,200 options allocated to Officers. These options are exercisable at $2.97 per share with a 10-year duration and vest equally every six months over a two-year period. The grants comply with TSX Venture Exchange policies and the company's stock option plan.

Positive

• None.

Negative

• Potential dilution of 627,200 shares (505,200 to Officers) at $2.97 per share

Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 627,200 incentive stock options to the company's employees, including 505,200 to the company's Officers, exercisable at a price of $2.97 per share for a period of 10 years and that vest equally every six months over a two-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company's stock option plan.

About NervGen

NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead molecule, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury and has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. For more information, visit www.nervgen.com and follow NervGen on X, LinkedIn, and Facebook for the latest news on the company.

Contacts

Huitt Tracey, Investor Relations
htracey@nervgen.com
604.537.2094

Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241357

FAQ

How many stock options did NervGen Pharma (NGENF) grant in February 2025?

NervGen Pharma granted 627,200 incentive stock options, with 505,200 options allocated to company Officers.

What is the exercise price for NGENF's February 2025 stock options?

The stock options are exercisable at $2.97 per share.

What is the vesting schedule for NervGen Pharma's (NGENF) 2025 stock options?

The stock options vest equally every six months over a two-year period.

What is the expiration period for NGENF's February 2025 stock options?

The stock options have a 10-year exercise period.